Smith D G, Harlan L C, Hawthorne V M
Department of Health Services, Management and Policy, School of Public Health, University of Michigan, Ann Arbor 48109.
J Clin Epidemiol. 1989;42(2):111-8. doi: 10.1016/0895-4356(89)90084-x.
To evaluate the differential charges for treating end-stage renal disease (ESRD) associated with diabetes mellitus, Medicare billing data are analyzed. The charges of 244 patients in the Michigan Kidney Registry identified as having (ESRD) from diabetes are compared with charges of 902 nondiabetic patients. Average annual charges for ESRD treatment for diabetics are +29,671 (+/- 27,662) which are +4695 (+/- 1344) higher than charges for nondiabetics. The majority of the difference (84.3%) is attributable to higher inpatient hospital charges. Most of the remainder (14.5%) is attributable to higher physician and medical supply charges. Charges for treatment of diabetics are higher on all modalities of treatment, but differences are not significant among modalities.
为评估治疗与糖尿病相关的终末期肾病（ESRD）的差异费用，对医疗保险计费数据进行了分析。将密歇根肾脏登记处确定患有糖尿病性ESRD的244例患者的费用与902例非糖尿病患者的费用进行比较。糖尿病患者ESRD治疗的平均年费用为29,671美元（±27,662美元），比非糖尿病患者的费用高出4695美元（±1344美元）。差异的大部分（84.3%）归因于较高的住院医院费用。其余大部分（14.5%）归因于较高的医生和医疗用品费用。糖尿病患者在所有治疗方式上的治疗费用都较高，但各治疗方式之间的差异不显著。
